Medical Scientist Training Program (CLS), University of Rochester School of Medicine & Dentistry, Rochester, New York; Department of Neurology (EKP, AB, BZM, BS), University of Rochester Medical Center, Rochester, New York; Department of Ophthalmology (ZRW), University of Rochester Medical Center, Rochester, New York; Department of Neurosurgery (ZRW, BZM), University of Rochester Medical Center, Rochester, New York; and Department of Psychology (BZM), Carnegie Mellon University, Pittsburgh, Pennsylvania.
Address correspondence to Bogachan Sahin, MD, PhD, Department of Neurology, University of Rochester, 601 Elmwood Avenue, Box 681, Rochester, NY 14642; E-mail: [email protected]
Supported by R01NS089609 (BZM), P30EY001319 (University of Rochester Center for Visual Sciences), the Schmitt Program on Integrative Brain Research (B.Z.M., B.S.), the University of Rochester Department of Neurology (B.Z.M., B.S.), and Research to Prevent Blindness (Z.R.W.). Preparation of this manuscript was supported by the National Institutes of Health grant F30EY027988 (C.L.S.), 2T32NS007338 (A.B.), K12HD093427 (A.B.), and R01EY028535 (B.Z.M.).
B.Z. Mahon is CSO and cofounder of MindTrace Technologies Inc, which licenses software from Carnegie Mellon University to predict neurologic recovery from brain mapping (PCT/US2019/064015). The remaining authors report no conflicts of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jneuro-ophthalmology.com).
